Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 8/20 | 0.41 |
| ▸ | PLD2 | O14939 | 6/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641078 | 0.86 | MDM2 (0.46) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL639917 | 0.85 | DRD2 (0.43) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL639583 | 0.84 | DRD2 (0.43) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL640105 | 0.83 | DRD2 (0.42) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL642360 | 0.82 | DRD2 (0.47) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL640560 | 0.81 | DRD2 (0.52) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL639709 | 0.78 | KDM4E (0.40) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL639981 | 0.76 | KDM4E (0.39) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL639980 | 0.76 | KDM4E (0.39) | DRD2SLC6A4HTR1AADRA2AHTR2A | |
| SCHEMBL640224 | 0.75 | DRD2 (0.41) | DRD2SLC6A4CHRM1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | DRD2 519/4885SLC6A4 644/4885HTR1A 268/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | DRD2 519/4885SLC6A4 644/4885HTR1A 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.